查詢結果分析
相關文獻
- Non-Small-Cell Lung Cancer in Patients Older than Eighty Years
- 三度空間隨形放療于非小細胞肺癌治療之應用
- 中醫藥輔助西醫癌症治療
- Recent Advances in Systemic Therapy for Non-Small Cell Lung Cancer in Elderly Patients
- 非小細胞肺癌之放射線治療
- Survival Benefit of Uracil-Tegafur (UFT) for AJCC 7th Pathologic Stage IB Non-Small Cell Lung Cancer Patients: A Propensity Score Matching Study
- Revisiting Squamous Cell Carcinoma of the Lungs--A Disease Given Less Attention
- Pemetrexed Followed by Docetaxel or a Reverse Sequence in Non-Small-Cell Lung Cancer
- Ductal Carcinoma of the Submandibular Gland
- 一位老年胃癌病患的居家化療經驗
頁籤選單縮合
題名 | Non-Small-Cell Lung Cancer in Patients Older than Eighty Years=年齡超過80歲的非小細胞肺癌 |
---|---|
作者姓名(中文) | 周昆達; 陳育民; 林桂枝; 蔡俊明; 李毓芹; 彭瑞鵬; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 26:1 2010.02[民99.02] |
頁次 | 頁3-11 |
分類號 | 417.7355 |
關鍵詞 | 化療; 老人; 非小細胞肺癌; 放療; 支持性療法; Chemotherapy; Elderly; Non-small-cell lung cancer; Radiotherapy; Supportive care; |
語文 | 英文(English) |
中文摘要 | 目的:回顧本院年齡超過80 歲的非小細胞肺癌病患病歷資料,以確定這類年紀很大的病 患是否可由特定治療獲得益處。 病患與方法:針對西元1996 至2000 年,在台北榮總診斷非小細胞肺癌的年齡超過80 歲 之病患基本資料、期別、病理分類,首次治療方式,與存活時間登記。再將病患存活時 間與臨床特點作統計分析。 結果:共有6906 位肺癌病患於1996 年至2000 年在本院診斷,內含5148 (74.5%)位非小 細胞肺癌。其中,245 位年齡超過80 歲,包括139 位接受特定治療(TG),106 位接受支 持性療法(SCG)。特定治療(TG)包括手術、化療,或放療。中值存活時間在TG 組是8 個月,在SCG 組是3 個月(p<0.001),一年存活率在TG 組36%,在SCG 組是18.9%。 在SCG 組的病患活動力較差,分期也相對較TG 組嚴重。當活動力介於0 與2 之間的第 ⅢB 與第Ⅳ期病患接受放療、化療,或支持性療法時,中值存活時間各為6 個月、7 個月、 與4 個月(p=0.703)。第Ⅳ期病患接受特定治療中值存活時間是8 個月,在支持性療組是3 個月(p=0.165)。 結論:雖然統計上沒有達到有意義差別,年齡很大的非小細胞肺癌病患還是可以用治療 得到延長存活,如使用手術、放療,或化療。 |
英文摘要 | Purpose: We reviewed data from our hospital-based cancer registry and chart records to determine if non-small lung cancer (NSCLC) patients older than eighty years benefit from specific treatment. Patients and Methods: Data of demographics, stage, histology, initial treatment modality, and survival status were obtained from all NSCLC patients older than eighty years registered at Taipei Veteran General Hospital from 1996 to 2000 (before era of targeted therapy). Patient survival and clinical characteristics were analyzed and compared statistically. Results: From 1996 to 2000, 6906 patients with lung cancer were diagnosed in our hospital, including 5148 (74.5%) with NSCLC. Of all NSCLC patients, 245 were older than eighty years, including 139 in the treatment group (TG) and 106 in the supportive care group (SCG). Specific treatment for patients in TG consisted of surgery, chemotherapy, and/or primary radiotherapy. The median survival time was 8 months in the TG and 3 months in the SCG (p< 0.001). The 1-year survival rate was 36% in the TG and 18.9% in the SCG. Patients in the SCG had a worse performance status and more advanced stage than those in the TG (p<0.001 and p=0.001, respectively). Multivariate analysis by Cox regression identified performance status, stage and identity as veteran as independent predictors for survival. When patients with stage IIIB or IV and a performance status of 0 to 2 were considered, patients who received radiotherapy, chemotherapy and supportive care alone had median survivals of 6, 7 and 4 months, respectively (p= 0.703). Stage IV patients with a performance status of 0 to 2 had a median survival of 8 months in TG and 3 months in SCG (p=0.165). Conclusions: Very old patients with advanced NSCLC may benefit from specific treatment, such as surgery, radiotherapy, or chemotherapy, although without statistical significance. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。